RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update
November 27, 2023 19:43 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Welcomes Prof. Artem Cherkasov to the Company’s Scientific Advisory Board
November 27, 2023 09:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
November 20, 2023 09:13 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update
August 29, 2023 08:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Results from 2023 Annual General Meeting
June 28, 2023 22:55 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, June 28, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSXV: RKV) (the “Company”), a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Q1 2023 Financial Results and Provides Corporate Update
May 31, 2023 09:05 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 31, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Closing of $1.5 Million Convertible Debenture Financing
May 29, 2023 20:57 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (“Rakovina” or the “Company”) (TSX-V: RKV) is pleased to announce that it has closed its previously announced...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces 2022 Financial Results and Convertible Debenture Financing
May 01, 2023 22:44 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 01, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based on...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Presentation of New kt-3000 Series Data at AACR Annual Meeting
April 20, 2023 12:47 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (the “Company”) (TSXV:RKV) today announced the presentation of new data describing the progress of the...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics to Present at the Emerging Growth Conference on April 19, 2023
April 17, 2023 18:18 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 17, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“Rakovina” or the “Company”) is pleased to announce that it has been invited to present at...